Piper Sandler analyst Biren Amin initiates coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight rating and announces Price Target of $157.
Piper Sandler Initiates Coverage On Sarepta Therapeutics With Overweight Rating, Announces Price Target of $157
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.